Identification and targeting of tumor escape mechanisms: A new hope for cancer therapy?

Current Pharmaceutical Design

Volumn 9, Issue 25, 2003, Pages 2009-2023

  Bergmann Leitner, Elke S ^a   Duncan, Elizabeth H ^a   Leitner, Wolfgang W ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Drug resistance; Immunotherapy; Radio resistance; Tumor escape

Indexed keywords

ANTINEOPLASTIC AGENT; BIRICODAR; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN DERIVATIVE; DAUNORUBICIN; DEXNIGULDIPINE; DEXVERAPAMIL; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GLYCOPROTEIN P; GRAMICIDIN; LANIQUIDAR; METHOTREXATE; METHYLNITROSOUREA; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROCARBAZINE; PROTEIN INHIBITOR; TARIQUIDAR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VINBLASTINE; VINCRISTINE; ZOSUQUIDAR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE PHASE; CELL HYPOXIA; CELL MUTANT; CELL TRANSFORMATION; DRUG MECHANISM; DRUG TARGETING; DRUG TRANSPORT; HIGH RISK PATIENT; HUMAN; MISMATCH REPAIR; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TREATMENT FAILURE; TUMOR CELL; TUMOR ESCAPE;

DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; HUMANS; NEOPLASMS; RADIATION TOLERANCE; RADIOIMMUNOTHERAPY; TUMOR ESCAPE;

EID: 0141587880     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454199     Document Type: Review

References (189)

1. Restifo NP, Antony PA, Finkelstein SE, Leitner WW, Surman DP, Theoret MR, et al. Assumptions of the tumor 'escape' hypothesis. Semin Cancer Biol 2002; 12: 81-6.
2. Petersen C, Zips D, Krause M, Schone K, Eicheler W, Hoinkis C, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 2001; 51: 483-93.
3. Withers HR, Taylor JMG, Maciejeweski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Act Oncol 1988; 27: 131-46.
4. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
5. Höckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15.
6. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001; 28/2 Suppl: 29-35.
7. Ruan H, Deen DF. Use of hypoxia-regulated gene expression in tumor-specific gene therapy. Curr Opin Investig Drugs 2001; 2: 839-43.
8. Kaanders JHAM, Bussink J, Kogel AJvd. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002; 3: 728-37.
9. Siemann DW, Hill RP, Bush RS. The importance of the pre-irradiation breathing times of O2 and carbogen (5%Co2; 95%O2) on the in vivo radiation response of a murine sarcoma. Int J Radiat Oncol Biol Phys 1977; 2: 903-11.
10. Rojas A, Denekamp J, Johns H, Kjellen E, Tsang R, Nilsson P, et al. Nicotinamide as a repair inhibitor in vivo: studies using single and fractionated X-ray doses in mouse skin and kidneys. Radiat Res 1996; 145: 419-31.
11. Horsman MR, Chaplin DJ, Brown JM. Tumor sensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res 1989; 118: 139-50.
12. Chaplin DJ, Horsman MR, Trotter MJ. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J Natl Cancer Inst 1990; 82: 672-76.
13. Brown DM, Evans JW, Brown JM. The influence of inhibitors of poly (ADP-ribose) polymerase on X-ray-induced potentially lethal damage repair. Br J Cancer Suppl 1984; 6: 27-31.
14. Kelleher DK, Vaupel P. Nicotinamide exerts different acute effects on microcirculatory function and tissue oxygenation in rat tumors. Int J Radiat Oncol Biol Phys 1993; 26: 95-102.
15. Davis TW, Wilson-Van Patten C, Meyers M, Kunugi KA, Cuthill S, Reznikoff C, et al. Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res 1998; 58: 767-78.
16. Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, et al. Correction of hypermutability, N-methyl-N′-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6. Cancer Res 1997; 57: 3949-55.
17. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, et al. Involvement of the mismatch repair system in temozolomide induced apoptosis. Mol Pharmacol 1998; 54: 334-41.
18. Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, et al. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells. Clin Cancer Res 1997; 3: 1763-7.
19. Drummond JT, Anthoney A, Brown R, Modrich P. Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem 1996; 271: 19645-8.
20. DeWeese T, Shipman J, Larrier N. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflincited by lowlevel radiation. Proc Natl Acad Sci 1998; 95: 11915-20.
21. Zeng M, Narayanan I, Xu X. Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways. Cancer Res 2000; 60: 4889-93.
22. Berry SE, Kinsella TJ. Targeting DNA mismatch repair for radiosensitization. Sem Radiat Oncol 2001; 11: 300-15.
23. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 2002; 62: 4671-7.
24. Shen H, Kauvar L, Tew KD. Importance of glutathione and associated enzymes in drug response. Oncol Res 1997; 9: 295-302.
25. Chen C-J, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381-9.
26. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
27. Ramachandra M, Ambudkar SV, Chen D, Hrycyna CA, Dey S, Gottesman MM, et al. Human P-glycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 1998; 37: 5010-9.
28. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
29. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-302.
30. Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, et al. Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. J Natl Cancer Inst 1999; 91: 1647-53.
31. Bradshaw DM, Arceci R. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 1998; 16: 3674-90.
32. Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, et al. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999; 93: 787-95.
33. Yamada M, O'Regan E, Brown R, Karran P. Selective recognition of a cisplatin-DNA adduct in human mismatch repair proteins. Nucleic Acids Res 1997; 25: 491-6.
34. Leung SY, Chan TL, Chung LP, Chan AS, Fan YW, Hung KN, et al. Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol 1998; 153: 1181-4.
35. Swann PF, Waters TR, Moulton DC, Zu YZ, Zheng Q, Edwards M, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273: 1109-11.
36. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001; 61: 5193-201.
37. Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45-52.
38. Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, et al. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 2000; 6: 1415-21.
39. Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB, et al. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival. J Clin Oncol 2000; 18: 87-93.
40. Venditti M, Iwasiow B, Orr FW, Shiu RP. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 2002; 99: 35-42.
41. Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, Mottolese M, et al. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. Clin Cancer Res 1999; 5: 2588-95.
42. Bos JL. ras oncogenes in human cancer; a review. Cancer Res 1989; 49: 4682-9.
43. Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64: 235-48.
44. Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000; 5: 24-33.
45. Fernandes RS, McGowan AJ, Cotter TG. Mutant H-ras overexpression inhibits drug and UV induced apotosis. Anticancer Res 1996; 16: 1691-705.
46. Peli J, Schroter M, Rudaz C, Hahne M, Meyer C, Reichmann E, et al. Oncogenic ras inhibits fas ligand-mediated apoptosis by downregulating the expression of fas. EMBO J 1999; 18: 1824-31.
47. Bergmann-Leitner ES, Abrams SI. Positive and negative consequences of soluble Fas ligand produced by an antigen-specific CD4(+) T cell response in human carcinoma immune interactions. Cell Immunol 2001; 209: 49-62.
48. Mauro MJ, Druker BJ. Chronic myelogenous leukemia. Curr Opin Oncol 2001; 13: 3-7.
49. Fuchs EJ, Bedi A, Jones RJ, Hess AD. Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res 1995; 55: 463-6.
50. Plo I, Lautier D, Casteran N, Dubreuil P, Arock M, Laurent G. Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cgamma. Oncogene 2001; 20: 6752-63.
51. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998; 16: 3158-3168.
52. Piche A, Rancourt C. Gene therapy to overcome drug resistance in cancer: targeting key regulators of the apoptotic pathway. Curr Gene Ther 2001; 1: 317-324.
53. Fuchs EJ, McKenna KA, Bedi A. p53-dependent DNA damage-induced apoptosis requires Fas/Apo-1-independent activation of CPP32beta. Cancer Res 1997; 57: 2550-4.
54. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994; 79: 329-39.
55. Adams JM, Cory S. The bcl-2 protein family:arbiters of cell survival. Science 1998; 281: 1322-26.
56. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Gene & Development 1999; 13: 1899-1911.
57. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL-2 family and cell death. Blood 1996; 88: 386-401.
58. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7: 541-46.
59. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, et al. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogene 1995; 11: 1217-1228.
60. Reed JC. Regulation of apoptosis by Bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 1995:
61. Gill J, Yamamoto H, Zapata JM, Reed JC, Perucho M. Impairment of the proapoptotic activity of Bax by missense mutation found in gastrointestinal cancers. Cancer Res 1999; 59: 2034-2037.
62. Meijerink JPP, Mensink EJBM, Wang K, Sedlak TW, Sloetjes AW, de Witte T, et al. Hematopoetic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998; 91: 2991-2997.
63. Tai Y-T, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998; 16: 2583-2590.
64. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, et al. Association between cisplatin resistance and mutation of p53 gene and reduxed bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-562.
65. Wagener C, Bargou EC, Daniel PT, Bommert K, Mapara MY, Royer HD, et al. Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 1996; 67: 138-41.
66. Strobel T, Swanson L, Korsmeyer SJ, Cannistra SA. BAX enhances paclitacel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci 1996; 93: 14094-14099.
67. Strobel T, Stine-Kathrein K, Lan BC, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res 1998; 58: 4776-4781.
68. Strobel T, Tai Y-T, Korsmeyer SJ, Cannistra SA. BAC partly reverses paclitaxel reistance in human ovarian cancer cells. Oncogene 1998; 15: 2419-27.
69. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of human BAX gene. Cell 1995; 80: 293-99.
70. Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, et al. Induction of BAC by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 1994; 9: 3743-51.
71. Reed JC. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 199; 11: 68-75.
72. Marte BM, Downward J. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 1997; 22: 355-358.
73. Gajewski TF, Thompson CB. Apoptosis meets signal transduction:eliminatio of a BAD influence. Cell 1996; 87: 589-592.
74. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 1994; 29: 41-49.
75. Kolata G. Oncogenes give breast cancer prognosis. Science 1987; 235: 160.
76. Uhlman DL, Nguyen P, Manivel JC, Zhang G, Hagan K, Farley E, et al. Epidermal growth factor receptor and transforming growth factor alpha expression i papillary and non papillary renal cell carcinoma: correlation with metastatic behaviour and progress. Clin Cancer Res 1995; 1: 913-920.
77. Page C, Lin HJ, Castle VP, Nunez G, Huang M, Lin J. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res 2000; 20: 407-46.
78. Teitz T, Wei T, Valentine MB, Vanin EF, Frenet J, Valentine VA, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529-35.
79. Joseph B, Ekedahl J, Sirzen F, Lewensohn R, Zhivotovsky B. Differences in expression of pro-caspases in small cell and non-small cel lung carcinoma. Biochem Biophys Res Commun 1999; 262: 381-7.
80. Schwartz S, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res 1999; 59: 2995-3002.
81. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 2001; 50: 445-55.
82. Ashkenazi A, Dixit VM. Death receptors: signalling and modulation. Science 1998; 281: 1305-8.
83. Yuan J. Transducing signals of life and death. Curr Opin Cell Biol 1997; 9: 247-51.
84. Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabbeele P, Fiers W. Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett 1997; 410: 96-106.
85. Thornberry N, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-16.
86. Elnemr A, Ohta T, Yachie A, Kayahara M, Kitagawa H, Fujimura T, et al. Human pancreatic cancer cells disable function of fas receptors at several levels in fas signal transduction pathway. Int J Cancer 2001; 18: 311-16.
87. Bergmann-Leitner ES, Abrams SI. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL. J Immunol 2000; 164: 4941-54.
88. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-5.
89. Wallach D. Placing death under control. Nature 1997; 388: 123-6.
90. Deveraux Q, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev 1998; 13: 239-52.
91. Tamm I, Kornblau SM, Segall H, Krajewski S, Welsh K, Kitada S, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
92. Deveraux Q, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell death proteases. Nature 1997; 388: 300-304.
93. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247-59.
94. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-4.
95. Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M. FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998; 161: 3936-42.
96. Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 2000; 10: 640-3.
97. Jaattela M. Escaping cell death: surivival proteins in cancer. Exp Cell Res 1999; 248: 30-43.
98. Wang XY, Li Y, Manjili MH, Repasky EA, Pardoll DM, Subjeck JR. Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor. Cancer Immunol.Immunother. 2002; 51: 311-9.
99. Manjili MH, Wang XY, Park J, Facciponte JG, Repasky EA, Subjeck JR. Immunotherapy of cancer using heat shock proteins. Front Biosci 2002; 7: d43-52.
100. Piche A, Rancourt C. A role for intracellular immunization in chemosensitization of tumor cells? Gene Therapy 1999; 6: 1202-1209.
101. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Phase I trial of paclitaxel plus megestrol acetate in patients with refractory ovarian cancer. Clin Cancer Res 2000; 6: 4201-4.
102. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory melanoma. Cancer 1995; 75: 815-20.
103. Maubant S, Staedel C, Gauduchon P. Integrins, cell response to anti-tumor agents and chemoresistance. Bull Cancer 2002; 89: 923-34
104. Ingber DE. Cancer as a disease of epithelial-mesenchymal interactions and extracellular matrix regulation. Differentiation 2002; 70: 547-60.
105. Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell 1992; 69: 11-25.
106. Parise LV, lee J, Juliano RL. New aspects of integrin signaling in cancer. Semin Cancer Biol 2000; 10: 407-14.
107. Damiano JS. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets 2002; 2: 37-43.
108. Galucci S, Lolkema M, Matzinger P. Natural adjuvants; endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-1255.
109. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996; 8: 271-80.
110. Medzhitov R, Janeway C. Innate immune recognitiion: mechanisms and pathways. Immunol Res 2000; 173: 89-97.
111. Whiteside TL, Herberman RB. The role of natural kille cells in immune surveillance of cancer. Curr Opin Immunol 1995; 7: 704-10.
112. Schultze JL, Bohlen H. Influence of genomics on cancer vaccine development from guess to prediction. Curr Pharm Des 2002; 19: 1735-48.
113. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol rev 1999; 170: 85-100.
114. Touloukian CE, Leitner WW, Robbins PF, Li YF, Kang X, Lapointe R, et al. Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Res 2002; 62: 5144-7.
115. Abrams SI, Hand PH, Tsang KY, Schlom J. Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 1996; 23: 118-34.
116. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180: 1-4.
117. Hodge JW, Schlom J, Donohue SJ, Tomaszewski JE, Wheeler CW, Levine BS, et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995; 63: 231-7.
118. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002; 62: 6944-51.
119. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405-31.
120. Leitner WW, Hwang LN, De Veer MJ, Zhou A, Silverman RH, Williams BR, et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 2003; 9: 33-39.
121. Grossmann ME, Davila E, Celis E. Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother 2001; 24: 237-41.
122. Restifo NP. Hierarchy, tolerance, and dominance in the antitumor T-cell response. J Immunother 2001; 24: 193-4.
123. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17: 737-47.
124. Touloukian CE, Leitner WW, Schnur RE, Robbins PF, Li Y, Southwood S, et al. Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1. J Immunol 2003; 170: 1579-85.
125. Schwartz RH. T Cell Anergy. Annu Rev Immunol 2002;
126. Harding C, Heuser I, Stahl P. Endocytosis and intracellular processing of transferrin and colloidal gold-transferrin in rat reticulocytes: demonstration of a pathway for receptor shedding. Eur J Cell Biol 1984; 35: 256-63.
127. Kurts C. Cross-presentation: inducing CD8T cell immunity and tolerance. J Mol Med 2000; 78: 326-32.
128. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells; molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487-94.
129. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25: 340-7.
130. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-8.
131. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89-95.
132. Cabrera T, Collado A, Fernandez MA, Ferron A, Ruiz-Cabello F, Garrido F. High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. Tissue Antigens 1998; 52: 114-23.
133. Algarra I, Collado A, Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res 1997; 27: 95-102.
134. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment. Int J Cancer 2001; 94: 243-51.
135. Giacomini P, Giorda E, Fraioli R, Nicotra MR, Vitale N, Setini A, et al. Low prevalence of selective human leukocyte antigen (HLA)-A and HLA-B epitope losses in early-passage tumor cell lines. Cancer Res 1999; 59: 2657-67.
136. Paschen A, Mendez RM, Jimenez P, Sucker A, Ruiz-Cabello F, Song M, et al. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int J Cancer 2003; 103: 759-67.
137. Sanda MG, Restifo NP, Walsh JC, Kawakami Y, Nelson WG, Pardoll DM, et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995; 87: 280-5.
138. Yang T, McNally BA, Ferrone S, Liu Y, Zheng P. A single nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J Biol Chem 2003;
139. Seliger B, Hohne A, Jung D, Kallfelz M, Knuth A, Jaeger E, et al. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp Hematol 1997; 25: 608-14.
140. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-72.
141. Korkolopoulou P, Kaklamanis L, Pezzella F, Harris AL, Gatter KC. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996; 73: 148-53.
142. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2: 667-73.
143. Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998; 160: 1224-32.
144. Singh B, Lucci A. Role of cyclooxigenase-e in breast cancer. J Surg Res 2002; 108: 173-9.
145. Konno H, Baba M, Shoji T, Ohta M, Suzuki S, Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 2002; 19: 527-34.
146. Fujita H, Koshida K, Keller ET, Takahashi Y, Yoshimoto T, Namiki M, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 2002; 53: 232-40.
147. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: upregulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58: 1208-16.
148. Lee JJ, Takei M, Hori S, Inoue Y, Harada Y, Tanosaki R, et al. The role of PGE(2) in the differentiation of dendritic cells: how do dendritic cells influence T-cell polarization and chemokine receptor expression? Stem Cells 2002; 20: 448-59.
149. Sun Y, Tang XM, Half E, Kuo MT, Sinicrope FA. Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent pathway in human colon cancer cells. Cancer Res 2002; 62: 6323-8.
150. Bol DK, Rowley RB, Ho CP, Pilz B, Dell J, Swerdel M, et al. Cyclooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res 2002; 62: 2516-21.
151. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP. Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res 2000; 60: 4044-8.
152. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunol Lett 2002; 82: 85-91.
153. Girolomoni G, Ricciardi-Castagnoli P. Dendritic cells hold promise for immunotherapy. Immunol Today 1997; 18: 102-4.
154. Salazar-Onfray F, Charo J, Petersson M, Freland S, Noffz G, Qin Z, et al. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 1997; 159: 3195-202.
155. Zeidler R, Eissner G, Meissner P, Uebel S, Tampe R, Lazis S, et al. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. Blood 1997; 90: 2390-7.
156. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997; 27: 1229-35.
157. Sharma S, Stolina M, Lin Y, Gardner B, Miller PW, Kronenberg M, et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J Immunol 1999; 163: 5020-8.
158. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Sem Cancer Biol 2002; 12: 43-50.
159. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implication for tumor immune escape. Science 1996; 274: 1363-66.
160. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
161. Bennett M, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-75.
162. Restifo NP. Not so Fas: re-evaluating the mchanism of immune privilige and tumor escape. Nat Med 2000; 6: 493-5.
163. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci 1997; 94: 13862-7.
164. Zaks TZ, Chappel DB, Rosenberg SA, Restifo NP. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 1999; 162: 3273-9.
165. Ikeda M, Yoshikawa H, Liu J, Nakajima Y, Akahane Y, Tasaka K. Apoptosis-inducing protein derived from hepatocyte selectively induces apoptosis in lymphocytes. Immunology 2003; 108: 116-22.
166. Bergmann-Leitner ES, Abrams SI. Influence of interferon gamma on modulation of Fas expression by human colon carcinoma cells and their subsequent sensitivity to antigen-specific CD8+ cytotoxic T lymphocyte attac. Cancer Immunol Immunother 2000; 49: 193-207.
167. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK. Interferon gamma is required for activation-induced death of T lymphocytes. J Exp Med 2002; 196: 999-1005.
168. Screaton G, Xu XN. T cell life and death signalling via TNF-receptor family members. Curr Opin Immunol 2000; 12: 316-22.
169. Frank S, Ebert AD. Licence to kill tumors: how much hope is justified for TRAIL? Curr Pharm Des 2001; 7: 1689-701.
170. Inoue H, Shiraki K, Yamanaka T, Ohmori S, Sakai T, Deguchi M, et al. Functional expression of tumor necrosis factor-related apoptosis-inducing ligand in human colonic adenocarcinoma cells. Lab Invest 2002; 82: 1111-9.
171. Lukacher AE. IFN-γ suspends the killing license of anti-tumor CTLs. J Clin Invest 2002; 110: 1407-9.
172. Malmberg K-J, Levitsky V, Norell H, Teixera de Matos C, Carlston M, Schedvins K, et al. IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 202; 110: 1515-23.
173. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci 1999; 96: 6879-84.
174. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-9.
175. Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature 2002; 419: 734-8.
176. Menier C, Riteau B, Carosella ED, Rouas-Freiss N. MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal. Int J Cancer 2002; 100: 63-70.
177. Sakaguchi S, Takahashi T, Yamazaki S, Kuniyasu Y, Itoh M, Sakaguchi N, et al. Immunologic self tolerance maintained by T-cell-mediated control of self-reactive T cells: implications for autoimmunity and tumor immunity. Microbes Infect 2001; 3: 911-8.
178. Sonoda K-H, Exley M, Snapper S, Balk SP, Stein-Streilein J. CD1-reactive natural killer T cells are required for the development of systematic tolerance through an immune-priviliged site. J Exp Med 1999; 190: 1215-226.
179. Zeng DF, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, et al. Bone marrow Nk1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 1999; 189: 1073-81.
180. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression an skin cancer development: regulation by NK T cells. Nat Immunol 2000; 1: 521-5.
181. Augustin HG. Antiangiogenic tumour therapy: will it work? Trends Pharmacol Sci 1998; 19: 216-22.
182. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8: 1369-75.
183. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295: 1526-8.
184. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002; 8: 1765-80.
185. Czuczman MS. Combination chemotherapy and rituximab. Anticancer Drugs 2001; 12 Suppl 2: S15-9.
186. Heinzer H, Huland E, Huland H. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol 2001; 19: 111-9.
187. Brady F, Luthra SK, Brown GD, Osman S, Aboagye E, Saleem A, et al. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr Pharm Des 2001; 7(18): 1863-92.
188. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des 2002; 8(4): 319-42.
189. Frenkel GD, Caffrey PB. A prevention strategy for circumventing drug resistance in cancer chemotherapy. Curr Pharm Des 2001; 7(16): 1595-614.